A cost-utility analysis of therapy for amblyopia
A cost-utility analysis of therapy for amblyopia
复制标题
DOI：
10.1016/s0161-6420(02)01286-1
复制
发表时间：
2002-12-01
期刊：
影响因子：
13.7
通讯作者：
Beauchamp, GR
中科院分区：
文献类型：
--
作者：
Membreno, JH;Brown, MM;Beauchamp, GR
目的：评价弱视治疗的增量成本-效果。设计：成本-效用参考病例分析。方法。从第三方保险公司的角度，通过使用决策分析、文献中的循证数据和基于患者偏好的时间权衡效用值进行成本效用分析。数据库：患者衍生的时间权衡眼部效用值和美国眼科学会弱视治疗首选实践模式指南。干预：根据美国眼科学会首选实践模式使用药物和手术治疗儿童弱视。主要结果指标：美元结果：弱视治疗的成本和结果的折扣率为3%，治疗后每质量调整生命年（$/QALY）的成本和结果的折扣率为2281美元。敏感性分析，改变成本和效用值的10%，导致$/QALY的收益范围从2053美元到2509美元。结论：与其他医疗保健干预措施相比，弱视治疗似乎具有很高的成本效益。这些信息对卫生保健政策制定者越来越重要。眼科学2002;109：2265-2271（C）2002，美国眼科学会。
Objective: Evaluation of the incremental cost-effectiveness of therapy for amblyopia.Design: Cost-utility reference-case analysis.Methods. A cost-utility analysis was performed from a third-party insurer perspective by using decision analysis, evidence-based data from the literature, and patient preference-based time trade-off utility values.Database: Patient-derived time trade-off ocular utility values and the American Academy of Ophthalmology Preferred Practice Pattern guidelines for the treatment of amblyopia.Intervention: Treatment of childhood amblyopia using medical and surgical therapies per the American Academy of Ophthalmology Preferred Practice Pattern.Main Outcome Measure: Dollars (year 2001 nominal U.S. dollars) expended per quality-adjusted life-year ($/QALY) gained.Results: Treatment for amblyopia resulted in a $/QALY gained of $2281 with a discount rate of 3% for costs and outcomes. Sensitivity analysis, varying costs and utility values by 10%, resulted in a $/QALY gained range from $2053 to $2509.Conclusions: When compared with other interventions in health care, therapy for amblyopia seems to be highly cost-effective. This information is increasingly important for health care policy makers. Ophthalmology 2002;109:2265-2271 (C) 2002 by the American Academy of Ophthalmology.